Holders — by stockHoldings — by fund
Ishara Investments LP
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-09-30 · filed with the SEC up to 45 days after quarter end · CIK 0002111609
$121.0M
disclosed book value
40
positions
7.1%
largest position share
Positions, as of 2026-09-30
top 41 of 40 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | TVTXTRAVERE THERAPEUTICS INC | 145,000 | $8.5M | 7.1% |
| 2 | CYTKCYTOKINETICS INC | 128,000 | $8.4M | 7% |
| 3 | BBIOBRIDGEBIO PHARMA INC | 100,000 | $6.6M | 5.4% |
| 4 | ACADACADIA PHARMACEUTICALS INC | 320,000 | $6.4M | 5.3% |
| 5 | TARSTARSUS PHARMACEUTICALS INC | 70,000 | $5.5M | 4.5% |
| 6 | PTCTPTC THERAPEUTICS INC | 80,000 | $5.2M | 4.3% |
| 7 | PRAXPRAXIS PRECISION MEDICINES I | 17,000 | $5.0M | 4.1% |
| 8 | VERAVERA THERAPEUTICS INC | 150,000 | $4.8M | 4% |
| 9 | ARQTARCUTIS BIOTHERAPEUTICS INC | 180,000 | $4.8M | 3.9% |
| 10 | ANNXANNEXON INC | 1.1M | $4.7M | 3.9% |
| 11 | UTHRUNITED THERAPEUTICS CORP DEL | 8,000 | $4.3M | 3.6% |
| 12 | NAMSNEWAMSTERDAM PHARMA COMPANY | 160,000 | $3.9M | 3.2% |
| 13 | XERSXERIS BIOPHARMA HOLDINGS INC | 400,000 | $3.8M | 3.2% |
| 14 | CELCCELCUITY INC | 48,000 | $3.8M | 3.2% |
| 15 | DBVTDBV TECHNOLOGIES S A | 270,000 | $3.2M | 2.6% |
| 16 | VRDNVIRIDIAN THERAPEUTICS INC | 150,000 | $3.1M | 2.6% |
| 17 | ZNTLZENTALIS PHARMACEUTICALS INC | 1.1M | $3.0M | 2.5% |
| 18 | BMRNBIOMARIN PHARMACEUTICAL INC | 48,000 | $2.9M | 2.4% |
| 19 | BIIBBIOGEN INC | 12,000 | $2.7M | 2.2% |
| 20 | MLYSMINERALYS THERAPEUTICS INC | 100,000 | $2.5M | 2.1% |
| 21 | LGNDLIGAND PHARMACEUTICALS INC | 8,000 | $2.5M | 2.1% |
| 22 | RAREULTRAGENYX PHARMACEUTICAL IN | 160,000 | $2.4M | 2% |
| 23 | PCVXVAXCYTE INC | 40,000 | $2.3M | 1.9% |
| 24 | ORICORIC PHARMACEUTICALS INC | 160,000 | $2.2M | 1.8% |
| 25 | AXSMAXSOME THERAPEUTICS INC. | 10,000 | $1.8M | 1.5% |
| 26 | SLNSILENCE THERAPEUTICS PLC | 160,000 | $1.7M | 1.4% |
| 27 | BEAMBEAM THERAPEUTICS INC | 70,000 | $1.7M | 1.4% |
| 28 | BHVNBIOHAVEN LTD | 120,000 | $1.6M | 1.3% |
| 29 | RAREULTRAGENYX PHARMACEUTICAL INPUT | 1,000 | $1.5M | 1.2% |
| 30 | CTNMCONTINEUM THERAPEUTICS INC | 108,000 | $1.4M | 1.2% |
| 31 | GMABGENMAB A/S | 40,000 | $1.4M | 1.2% |
| 32 | NBIXNEUROCRINE BIOSCIENCES INC | 8,000 | $1.1M | 0.9% |
| 33 | MNPRMONOPAR THERAPEUTICS INC | 12,000 | $956,040 | 0.8% |
| 34 | MLTXMOONLAKE IMMUNOTHERAPEUTICS | 80,000 | $936,000 | 0.8% |
| 35 | SPRYARS PHARMACEUTICALS INC | 200,000 | $862,000 | 0.7% |
| 36 | IONSIONIS PHARMACEUTICALS INC | 16,000 | $714,400 | 0.6% |
| 37 | OLMAOLEMA PHARMACEUTICALS INC | 80,000 | $691,200 | 0.6% |
| 38 | LXRXLEXICON PHARMACEUTICALS INC | 320,000 | $600,000 | 0.5% |
| 39 | WVEWAVE LIFE SCIENCES INC | 160,000 | $592,000 | 0.5% |
| 40 | SVRASAVARA INC | 80,000 | $412,800 | 0.3% |
| 41 | GOSSGOSSAMER BIO INC | 24,000 | $284,400 | 0.2% |
Source: SEC Form 13F-HR, reporting period 2026-09-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.